# A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia

> **NCT00629681** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 217 (actual)

## Conditions studied

- Painful Diabetic Neuropathy and Post Herpetic Neuralgia

## Interventions

- **DRUG:** Pregabalin

## Key facts

- **NCT ID:** NCT00629681
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629681, "A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00629681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*